
|Videos|June 9, 2020
SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?
Author(s)Grant M. Gallagher
Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
The Latest on the Cyclosporiasis Outbreak: An FDA False Positive Test, and What Treatment Looks Like
2
Researching Repurposed Medications for Long COVID
3
Cyclosporiasis Case Count Tops 7000 as Lettuce Probe Continues
4
Once-Weekly Islatravir/Lenacapavir Meets Phase 3 Primary End Point
5




























































































































































